Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro

Olga Cain, Adriana O. Diaz-Quiñones, Jayne Ellis, Marxa L. Figueiredo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. In prostate tumor cells, IL-27 upregulated genes related to its signaling pathway while downregulating malignancy-related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL-27 modulated upregulation of genes related to its own signaling pathway as well as pro-osteogenic genes. In osteoclasts, IL-27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis-related genes. Furthermore, an osteogenesis-focused real-time PCR array revealed a more extensive profile of pro-osteogenic gene changes in both osteoblasts and osteoclasts. In T-lymphocyte cells, IL-27 upregulated several activation-related genes and also genes related to the IL-27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol.

Original languageEnglish (US)
Pages (from-to)1127-1136
Number of pages10
JournalJournal of Cellular Physiology
Volume228
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Interleukin-27
Crosstalk
Prostatic Neoplasms
Bone
Genes
Cells
Bone and Bones
Tumors
Osteoclasts
Down-Regulation
Osteoblasts
Osteogenesis
Prostate
Neoplasms
T-cells
Gene expression
In Vitro Techniques
T-Lymphocytes
Cellular Microenvironment
Gene Expression

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro. / Cain, Olga; Diaz-Quiñones, Adriana O.; Ellis, Jayne; Figueiredo, Marxa L.

In: Journal of Cellular Physiology, Vol. 228, No. 5, 05.2013, p. 1127-1136.

Research output: Contribution to journalArticle

Cain, Olga ; Diaz-Quiñones, Adriana O. ; Ellis, Jayne ; Figueiredo, Marxa L. / Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro. In: Journal of Cellular Physiology. 2013 ; Vol. 228, No. 5. pp. 1127-1136.
@article{d05580104acc4fa4b8f4483fd11ad0f9,
title = "Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro",
abstract = "Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. In prostate tumor cells, IL-27 upregulated genes related to its signaling pathway while downregulating malignancy-related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL-27 modulated upregulation of genes related to its own signaling pathway as well as pro-osteogenic genes. In osteoclasts, IL-27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis-related genes. Furthermore, an osteogenesis-focused real-time PCR array revealed a more extensive profile of pro-osteogenic gene changes in both osteoblasts and osteoclasts. In T-lymphocyte cells, IL-27 upregulated several activation-related genes and also genes related to the IL-27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol.",
author = "Olga Cain and Diaz-Qui{\~n}ones, {Adriana O.} and Jayne Ellis and Figueiredo, {Marxa L.}",
year = "2013",
month = "5",
doi = "10.1002/jcp.24265",
language = "English (US)",
volume = "228",
pages = "1127--1136",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro

AU - Cain, Olga

AU - Diaz-Quiñones, Adriana O.

AU - Ellis, Jayne

AU - Figueiredo, Marxa L.

PY - 2013/5

Y1 - 2013/5

N2 - Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. In prostate tumor cells, IL-27 upregulated genes related to its signaling pathway while downregulating malignancy-related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL-27 modulated upregulation of genes related to its own signaling pathway as well as pro-osteogenic genes. In osteoclasts, IL-27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis-related genes. Furthermore, an osteogenesis-focused real-time PCR array revealed a more extensive profile of pro-osteogenic gene changes in both osteoblasts and osteoclasts. In T-lymphocyte cells, IL-27 upregulated several activation-related genes and also genes related to the IL-27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol.

AB - Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. In prostate tumor cells, IL-27 upregulated genes related to its signaling pathway while downregulating malignancy-related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL-27 modulated upregulation of genes related to its own signaling pathway as well as pro-osteogenic genes. In osteoclasts, IL-27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis-related genes. Furthermore, an osteogenesis-focused real-time PCR array revealed a more extensive profile of pro-osteogenic gene changes in both osteoblasts and osteoclasts. In T-lymphocyte cells, IL-27 upregulated several activation-related genes and also genes related to the IL-27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol.

UR - http://www.scopus.com/inward/record.url?scp=84873845022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873845022&partnerID=8YFLogxK

U2 - 10.1002/jcp.24265

DO - 10.1002/jcp.24265

M3 - Article

VL - 228

SP - 1127

EP - 1136

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 5

ER -